A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1213-1216

  Fleuridor, Richardson ^b   Zhong, Zhaojing ^b   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2E9; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGAL GENETICS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0031716168     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515688     Document Type: Article

References (15)

1. Pirofski L, Casadevall A. Cryptococcus neoformans: paradigm for the role of antibody in immunity. Zentralbl Bakteriol 1996;284:475-95.
2. - individuals. Clin Exp Immunol 1995;99:425-32.
3. Zhang H, Zhong Z, Pirofski L. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect Immun 1997; 65:1158-64.
4. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-702.
5. Pirofski L, Lui R, DeShaw M, Kressel AB, Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect Immun 1995;63:3005-14.
6. Zhong Z, Pirofski L. Antifungal activity of a human antiglucuronoxylomannan antibody. Clin Lab Diagn Immunol 1998;5:58-64.
7. H3 gene segment usage. J Infect Dis 1998;178:707-16.
8. Townsley-Fuchs J, Kam L, Fairhurst R, et al. Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J Clin Invest 1996;98:1794-801.
9. Zhong Z, Pirofski L. Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannan antibodies. Infect Immun 1996;64:3446-50.
10. Dromer F, Mathoulin S, Dupont B, Letenneur L, Ronin O. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. Clin Infect Dis 1996;23:91-6.
11. Szalai AJ, Briles DE, Volanakis JE. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun 1996;64:4850-3.
12. Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol 1995;155:190-202.
13. Brown EJ, Hosea SW, Hammer CH, Burch G, Frank MM. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest 1982;69:85-98.
14. Savoy AC, Lupan DM, Manalo PB, et al. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect Immun 1997;65:1800-7.
15. Griffin FM Jr. Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc Natl Acad Sci USA 1981;78:3853-7.